Indonesia Strives to Build a National Plasma-Derived Medicinal Ecosystem
The Indonesian government is currently focused on independently developing an ecosystem for plasma-derived medicinal products. This step is being taken to address challenges regarding the accessibility of these health products, which have long been an obstacle in many Southeast Asian countries, including Indonesia.
Plasma-derived medicinal products are medical items derived from human blood plasma components. These products are crucial for treating various serious illnesses, such as immune system disorders, burns, and other rare diseases. Until now, reliance on imported products has made the availability of these medicines limited and expensive.
Developing this ecosystem involves collaboration between the health sector, the pharmaceutical industry, and the Indonesian Red Cross. The primary focus is to increase domestic blood plasma processing capacity so that the needs of patients in hospitals across Indonesia can be met more quickly and affordably.
In addition to increasing medical self-sufficiency, this project is expected to strengthen national health resilience. By possessing its own processing facilities, Indonesia will no longer need to rely entirely on foreign supplies during global health crises or international supply chain disruptions.
Overall, this initiative is a strategic step toward improving the quality of healthcare services for the public. The government aims for national production of plasma-derived medicines to be fully operational soon in order to provide better health protection for all Indonesian citizens.